Funded Projects
Explore our currently funded projects. You may search with all three fields, then focus your results by applying any of the dropdown filters. After customizing your search, you may download results and even save your specific search for later.
Project # | Project Title | Research Focus Area | Research Program | Administering IC | Institution(s) | Investigator(s) | Location(s) Sort ascending | Year Awarded |
---|---|---|---|---|---|---|---|---|
1R01DA056608-01
Show Summary |
Endocannabinoid Targeting for Opioid Induced Respiratory Depression | Novel Therapeutic Options for Opioid Use Disorder and Overdose | Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose | NIDA | University of Arizona | MILNES, TALLY MARIE (contact); VANDERAH, TODD W | Tucson, Arizona | 2022 |
NOFO Title: HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R01 Clinical Trial Not Allowed)
NOFO Number: RFA-DA-22-031 Summary: This research project will investigate the cannabinoid receptor 2 protein (CB2R) as a novel therapeutic target for opioid-induced respiratory depression caused by fentanyl, oxycodone, and heroin. This study will shed light on how the endocannabinoid system in the brainstem works to control breathing under normal conditions and during opioid-induced respiratory depression. The research aims to determine whether activation of the CB2R with a brain-penetrant CB2R-binding molecule is safe and clinically useful for treating opioid overdose prevention and reversal. This research will pave the way for discovering new medications that activate CB2R to reduce opioid-related deaths. |
||||||||
2R44MD015912-03
Show Summary |
Clinical Optimization of Ultrasonic Drug Delivery Technologies for Underserved Minority U.S. Veterans in Chronic Pain | Cross-Cutting Research | Small Business Programs | NIMHD | ZETROZ SYSTEMS, LLC | LEWIS, GEORGE KENNETH | Trumbull, CT | 2023 |
NOFO Title: HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 - Clinical Trial Required)
NOFO Number: RFA-NS-20-010 Summary: Osteoarthritis is one of the most common joint diseases affecting Americans. Osteoarthritis is particularly high among veterans with a service-related disability. This project will develop and refine a wireless ultrasound device that increases the penetration of over-the-counter pain medications into the body, which is expected to reduce pain. The research will conduct safety and clinical testing toward commercializing this technology. |
||||||||
1R43NS120335-01
Show Summary |
Closed-Loop Micromagnetic Neuromodulation as a Non-Opioid Treatment for Neuropathic Pain | Cross-Cutting Research | Small Business Programs | NINDS | QUANTUM NANOSTIM | REILLY, THOMAS | Treasure Island, FL | 2021 |
NOFO Title: HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 – Clinical Trial Not Allowed)
NOFO Number: RFA-NS-20-011 Summary: Spinal cord stimulation (SCS) has been shown to provide effective relief for most people with chronic pain and eliminated the need for opioid therapy in more than half of those treated. However, traditional SCS approaches have encountered problems when glial cells coat the stimulation electrodes that distance the device from targeted neurons. This project will develop a novel hybrid Closed Loop Omnidirectional Neuromodulation with Electromagnetic fields (CLONE) system that is combined with magnetic-based stimulation to overcome glial coating of SCS electrodes, better target neurons in dorsal spine tissue, which may lead to better treatment of chronic neuropathic neck and low back pain. |
||||||||
1R41NS127637-01A1
Show Summary |
Protease-Activated-Receptor-2 Antagonists for Treatment of Migraine Pain | Cross-Cutting Research | Small Business Programs | NINDS | PARMEDICS, INC. | DEFEA, KATHRYN (contact); DUSSOR, GREGORY O | Temecula, CA | 2023 |
NOFO Title: HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Not Allowed)
NOFO Number: RFA-NS-20-009 Summary: There is a need for additional effective treatments for migraine, which affects more than 36 million people in the United States. This project will develop an oral medication to disrupt the biological processes that drive migraine pain, which include nerve inflammation in response to pain signals. |
||||||||
1R61DA057667-01
Show Summary |
CADENCE – Continuous and Data-drivEN CarE | Cross-Cutting Research | Translating Data 2 Action to Prevent Overdose | NIDA | UNIVERSITY OF SOUTH FLORIDA | FRYER, KIMBERLY (contact); MARSHALL, JENNIFER | Tampa, FL | 2022 |
NOFO Title: HEAL Initiative: HEAL Data2Action Innovation Projects (R61/R33 Clinical Trial Optional)
NOFO Number: RFA-DA-22-051 Summary: Maternal opioid use disorder is the leading cause of death for women who die within a year of giving birth. Many pregnant women do not have access to prenatal care and medications known to be standard of care for opioid use disorder. This project will create, measure, and evaluate costs for an interactive dashboard that collects and analyzes data about maternal, newborn, and infant outcomes for pregnancies affected by opioid use disorder. This research will also monitor mothers’ use of medications for opioid use disorder and the number of infants born with neonatal withdrawal syndrome that require medication treatment. |